About Anabios
Anabios is a company based in San Diego (United States) founded in 2009.. Anabios has raised $24.78 million across 12 funding rounds from investors including NIH, HHS and Ampersand Capital Partners. The company has 51 employees as of December 31, 2022. Anabios has completed 1 acquisition, including Cell Systems. Anabios offers products and services including Human Tissue and Cells, Functional Assays, Human Hepatocytes, and Human Precision-Cut Lung Slices. Anabios operates in a competitive market with competitors including Metrion Biosciences, Antibody Analytics, Quiver Bioscience, Zen-Bio and Pelago Bioscience, among others.
- Headquarter San Diego, United States
- Employees 51 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Anabios Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$24.78 M (USD)
in 12 rounds
-
Latest Funding Round
$6.5 M (USD), Series B
Jun 07, 2022
-
Investors
NIH
& 6 more
-
Employee Count
51
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Anabios
Anabios offers a comprehensive portfolio of products and services, including Human Tissue and Cells, Functional Assays, Human Hepatocytes, and Human Precision-Cut Lung Slices. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides human tissues for scientific research and drug testing.
Offers assays for evaluating drug effects on human tissues.
Specific human liver cells for research applications.
Human lung tissue slices for toxicity and efficacy studies.
Unlock access to complete
Unlock access to complete
Funding Insights of Anabios
Anabios has successfully raised a total of $24.78M across 12 strategic funding rounds. The most recent funding activity was a Series B round of $6.5 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Series B — $6.5M
-
First Round
First Round
(08 Sep 2011)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Series B - Anabios | Valuation |
investors |
|
| Sep, 2021 | Amount | Grant - Anabios | Valuation |
investors |
|
| Sep, 2021 | Amount | Grant - Anabios | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Anabios
Anabios has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Ampersand Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ampersand Capital Partners is focused on investments in healthcare and life sciences.
|
Founded Year | Domain | Location | |
|
Early-stage investments in Italian tech and life sciences are targeted.
|
Founded Year | Domain | Location | |
|
Angel Network for companies based in Southern California
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Anabios
Anabios has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cell Systems. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Primary cells, culture media, and reagents are developed and manufactured.
|
1989 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Anabios
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Anabios Comparisons
Competitors of Anabios
Anabios operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metrion Biosciences, Antibody Analytics, Quiver Bioscience, Zen-Bio and Pelago Bioscience, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Ion channel screening and cardiac safety profiling services are provided.
|
|
| domain | founded_year | HQ Location |
Antibody analytics and characterization services are provided.
|
|
| domain | founded_year | HQ Location |
Developer of transformational medicines for neurological disorders
|
|
| domain | founded_year | HQ Location |
Cell-based solutions are provided to accelerate therapy discovery and development.
|
|
| domain | founded_year | HQ Location |
Drug-target interactions are quantified via specialized assay services.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Anabios
Frequently Asked Questions about Anabios
When was Anabios founded?
Anabios was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Where is Anabios located?
Anabios is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Anabios a funded company?
Anabios is a funded company, having raised a total of $24.78M across 12 funding rounds to date. The company's 1st funding round was a Grant of $1.42M, raised on Sep 08, 2011.
How many employees does Anabios have?
As of Dec 31, 2022, the latest employee count at Anabios is 51.
What does Anabios do?
AnaBios provides contract research services for pre-clinical drug discovery which is entirely based on laboratory tests performed in living human tissues. It provides services for target selection and validation, lead optimisation, clinical candidate selection and clinical program de-risking through its proprietary Phase X platform. It offers its clients and partners full access to its assays and technologies that enable the study of ex-vivo human responses to drugs and the investigation of the molecular and functional basis of human physiology. The company focuses primarily on ex-vivo human studies for cardiovascular safety, pain and neurodegeneration. The company claims that its human-focused approach is a better predictor of safety and efficacy of drugs than the traditional in vitro or animal studies. The company also claims to have validated its technologies through its collaborations with pharma companies in US, Europe and Japan and has now initiated its own portfolio of drugs targeting CNS and Cardiovascular diseases. AnaBios has licensed a suite of patents for Nav1.7 sodium ion channel blockers from Purdue Pharma from which it will help in finding suitable candidates through its Phase X platform. The company also offers cardiac safety and toxicity and neurotoxicity services.
Who are the top competitors of Anabios?
Anabios's top competitors include Metrion Biosciences, Quiver Bioscience and Zen-Bio.
What products or services does Anabios offer?
Anabios offers Human Tissue and Cells, Functional Assays, Human Hepatocytes, and Human Precision-Cut Lung Slices.
How many acquisitions has Anabios made?
Anabios has made 1 acquisition, including Cell Systems.
Who are Anabios's investors?
Anabios has 7 investors. Key investors include NIH, HHS, Ampersand Capital Partners, U.S. Food and Drug Administration, and Principia SGR.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.